Pirraglia Paul A., Stafford Randall S., Singer Daniel E.
General Medicine Division, Massachusetts General Hospital, Boston, and the Stanford Center for Research in Disease Prevention, Palo Alto, Calif.
Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157. doi: 10.4088/pcc.v05n0402.
The introduction of selective serotonin reuptake inhibitors (SSRIs) represented a breakthrough in depression treatment due to their safety and ease of use. The purpose of this study was to extend previous work on trends in antidepressant use to include recent data and to provide more detailed analysis of prescribing trends for SSRIs and newer non-SSRI antidepressants, specifically in adult primary care practice. METHOD: Adult primary care visits from the National Ambulatory Medical Care Survey (NAMCS) between 1989 and 2000 were analyzed. Chi-square tests for trend and multivariable logistic regression models were utilized to examine patterns of antidepressant use over time. SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) and newer non-SSRI antidepressants (bupropion, mirtazapine, nefazodone, venlafaxine) were classified as newer agents. RESULTS: 89,424 adult primary care visits were recorded in the NAMCS during the period studied. Antidepressant use increased in primary care from 2.6% ( approximately 6 million visits) in 1989 to 7.1% ( approximately 20.5 million) in 2000 (p <.001). SSRI and newer non-SSRI use increased linearly from 1989 to 2000 (p <.001), with an adjusted odds ratio for use of 1.27 per year (95% confidence interval = 1.25 to 1.29). The increase in antidepressant use was due to these newer agents (13.5% of all antidepressant use in 1989 to 82.3% in 2000) with each new agent adding to a stable base of previously introduced newer antidepressant agents. CONCLUSIONS: The prevalence of antidepressant use in adult primary care has risen dramatically since 1989, largely reflecting use of newer agents. The detailed pattern of increased use of these medications is striking, with each new agent adding to aggregate use without concomitant decrease in previously introduced newer agents. Such trends reflect more widespread pharmacologic treatment of depressed primary care patients.
选择性5-羟色胺再摄取抑制剂(SSRI)的引入因其安全性和易用性,在抑郁症治疗方面代表了一项突破。本研究的目的是扩展先前关于抗抑郁药使用趋势的研究工作,纳入最新数据,并针对SSRI和新型非SSRI抗抑郁药的处方趋势提供更详细的分析,特别是在成人初级保健实践中。方法:分析了1989年至2000年期间美国国家门诊医疗调查(NAMCS)中的成人初级保健就诊情况。运用趋势卡方检验和多变量逻辑回归模型来研究抗抑郁药随时间的使用模式。将SSRI(西酞普兰、氟西汀、氟伏沙明、帕罗西汀、舍曲林)和新型非SSRI抗抑郁药(安非他酮、米氮平、奈法唑酮、文拉法辛)归类为新型药物。结果:在所研究期间,NAMCS记录了89424次成人初级保健就诊。初级保健中抗抑郁药的使用从1989年的2.6%(约600万次就诊)增加到2000年的7.1%(约2050万次)(p<.001)。从1989年到2000年,SSRI和新型非SSRI的使用呈线性增加(p<.001),每年使用的调整优势比为1.27(95%置信区间=1.25至1.29)。抗抑郁药使用的增加归因于这些新型药物(从1989年占所有抗抑郁药使用的13.5%到2000年的82.3%),每种新药都在先前引入的新型抗抑郁药稳定基础上增加使用量。结论:自1989年以来,成人初级保健中抗抑郁药的使用患病率大幅上升,主要反映了新型药物的使用。这些药物使用增加的详细模式令人瞩目,每种新药都增加了总使用量,而先前引入的新型药物的使用量并未随之减少。这种趋势反映了对初级保健中抑郁症患者进行更广泛的药物治疗。